Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 8:10 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1153–1176 of 17,144 matching trials from the live ClinicalTrials.gov search.
Conditions
Ovarian Cancer, Clear Cell Carcinoma, Endometrial Cancer, Cervical Carcinoma, Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Interventions
vudalimab
Biological
Lead sponsor
Xencor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
17
States / cities
Prescott, Arizona • La Jolla, California • Los Angeles, California + 12 more
Conditions
Neurofibromatosis Type 1
Interventions
Selumetinib granule formulation, Selumetinib capsule formulation
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
1 Year to 6 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
4
States / cities
Akron, Ohio • Philadelphia, Pennsylvania • Houston, Texas + 1 more
Conditions
Bladder Cancer
Interventions
ADXBLADDER
Diagnostic Test
Lead sponsor
Arquer Diagnostics Ltd
Industry
Eligibility
22 Years and older
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
13
States / cities
Denver, Colorado • Daytona Beach, Florida • Jeffersonville, Indiana + 10 more
Completed Phase 3 Interventional Results available

Study of Eteplirsen in DMD Patients

NCT02255552
Conditions
Duchenne Muscular Dystrophy (DMD)
Interventions
eteplirsen
Drug
Lead sponsor
Sarepta Therapeutics, Inc.
Industry
Eligibility
7 Years to 16 Years · Male only
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
37
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 32 more
Conditions
Cardiovascular Diseases, Heart Diseases, Coronary Disease, Atherosclerosis, Myocardial Infarction
Interventions
Simvastatin and Extended-Release niacin, Simvastatin
Drug
Lead sponsor
University of Washington
Other
Eligibility
45 Years and older
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
24
States / cities
Birmingham, Alabama • Phoenix, Arizona • Long Beach, California + 13 more
Conditions
Menopausal and Female Climacteric States
Interventions
Other: Placebo, GSK232802, PREMARIN
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
41
States / cities
Chandler, Arizona • Glendale, Arizona • Scottsdale, Arizona + 35 more
Conditions
Coagulation in Liver Transplantation
Interventions
Not listed
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Contraception
Interventions
Ulipristal Acetate, Levonorgestrel
Drug
Lead sponsor
Kimberly Myer
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
532 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
18
States / cities
Los Angeles, California • Sacramento, California • San Francisco, California + 14 more
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Verducatib, Placebo matching verducatib
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
1,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
18
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Palma, California + 14 more
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Clostridium Difficile Vaccine Efficacy Trial

NCT03090191
Conditions
Clostridium Difficile Infection
Interventions
Clostridium difficile vaccine, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
50 Years and older
Enrollment
17,535 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
220
States / cities
Athens, Alabama • Huntsville, Alabama • Mobile, Alabama + 145 more
Completed Not applicable Interventional Results available

Low-Level Laser in Head and Neck Chronic Lymphedema

NCT04482855
Conditions
Head and Neck Cancer, Lymphedema, Fibrosis
Interventions
Low-level laser
Device
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Non-small Cell Lung Cancer
Interventions
eribulin mesylate + erlotinib
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
50
States / cities
Bessemer, Alabama • Birmingham, Alabama • Beverly Hills, California + 47 more
Completed No phase listed Observational Accepts healthy volunteers

Healthy Human Control Blood Collection for Validation of Biomarker Assay

NCT02302885
Conditions
Healthy
Interventions
Blood collection
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years to 60 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Breast Cancer
Interventions
Trastuzumab deruxtecan, Capecitabine, Lapatinib, Trastuzumab
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
608 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
41
States / cities
Chandler, Arizona • Los Angeles, California • Monterey, California + 34 more
Conditions
Acute Myeloid Leukemia, Neutropenia, Infection
Interventions
CLT-008, G-CSF
Biological
Lead sponsor
Cellerant Therapeutics
Industry
Eligibility
55 Years and older
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
22
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 16 more
Conditions
Human Papilloma Virus
Interventions
Health Education Session
Behavioral
Lead sponsor
MEE Productions, Inc.
Other
Eligibility
Female only
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Platinum-resistant Ovarian Cancer
Interventions
Batiraxcept, Paclitaxel, Placebo
Drug · Other
Lead sponsor
Aravive, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
84
States / cities
Mobile, Alabama • Burbank, California • Los Angeles, California + 74 more
Completed Not applicable Interventional Results available

Ablation vs Drug Therapy for Atrial Fibrillation - Pilot Trial

NCT00578617
Conditions
Atrial Fibrillation, Arrhythmia
Interventions
Rate Control, Ablation Therapy, Rhythm control
Drug · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
10
States / cities
Birminham, Alabama • Los Angeles, California • Maywood, Illinois + 7 more
Conditions
Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA
Interventions
Arsenic Trioxide, Cytarabine, Dexamethasone, Idarubicin, Laboratory Biomarker Analysis, Mitoxantrone Hydrochloride, Quality-of-Life Assessment, Questionnaire Administration, Tretinoin
Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
12 Months to 21 Years
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2029
U.S. locations
152
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 121 more
Conditions
Heart Decompensation
Interventions
Nesiritide, Placebo
Drug
Lead sponsor
Scios, Inc.
Industry
Eligibility
18 Years and older
Enrollment
7,141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
171
States / cities
Huntsville, Alabama • Mobile, Alabama • Anchorage, Alaska + 168 more
Conditions
Schizophrenia
Interventions
Placebo, bitopertin [RO4917838]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
597 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
25
States / cities
Carson, California • Garden Grove, California • Long Beach, California + 19 more
Conditions
Treatment Resistant Depression
Interventions
Not listed
Lead sponsor
LivaNova
Industry
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
33
States / cities
Birmingham, Alabama • Costa Mesa, California • Los Angeles, California + 29 more
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Respimat inhaler, tiotropium+olodaterol (low dose), tiotropium + olodaterol (high dose), placebo to tiotropium+olodaterol
Device · Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years to 75 Years
Enrollment
404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
15
States / cities
Torrance, California • Hartford, Connecticut • Springfield, Illinois + 12 more
Conditions
Obesity
Interventions
semaglutide 2.4 mg, semaglutide 2.4 mg (placebo)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
Not listed
Enrollment
407 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
61
States / cities
Montgomery, Alabama • Phoenix, Arizona • Anaheim, California + 52 more